Source comparison
Tesamorelin Ipamorelin Blend Comparison
Tesamorelin GHRH receptor (anterior pituitary) Activates adenylyl cyclase → cAMP → GH secretory granule release 26–38 minutes Oxidative degradation of hexenoyl group; light and heat sensitivity Mimics endogenous GHRH; subject to receptor desensitization with c
This comparison does not assign a generated winner or score.
- Tesamorelin
- GHRH receptor (anterior pituitary)
- Activates adenylyl cyclase → cAMP → GH secretory granule release
- 26–38 minutes
- Oxidative degradation of hexenoyl group; light and heat sensitivity
- Mimics endogenous GHRH; subject to receptor desensitization with continuous exposure
- Ipamorelin
- GHS-R1a (ghrelin receptor)
- Mobilizes intracellular calcium → voltage-gated calcium channel opening → GH release
- ~2 hours
- Minimal. D-amino acids resist proteolytic cleavage
- Highly selective; does not co-release cortisol or prolactin like older GHRPs
- Tesamorelin + Ipamorelin Blend
- Both GHRH and ghrelin pathways
- Dual-pathway synergy: simultaneous activation produces 1.3–1.5× GH release vs monotherapy
- Governed by tesamorelin (~30 min)
- Tesamorelin component dictates overall stability; refrigerate at 2–8°C, use within 14 days
- Synergistic GH response; stability profile matches the weaker peptide (tesamorelin)